Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s traded shares stood at 1.45 million during the last session, with the company’s beta value hitting 1.71. At the close of trading, the stock’s price was $18.19, to imply an increase of 10.44% or $1.72 in intraday trading. The TNXP share’s 52-week high remains $1184.00, putting it -6409.07% down since that peak but still an impressive 62.84% since price per share fell to its 52-week low of $6.76. The company has a valuation of $101.69M, with an average of 1.36 million shares in intraday trading volume over the past 10 days and average of 1.53 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Tonix Pharmaceuticals Holding Corp (TNXP), translating to a mean rating of 1.00. Of 5 analyst(s) looking at the stock, 0 analyst(s) give TNXP a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -3.09.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
After registering a 10.44% upside in the last session, Tonix Pharmaceuticals Holding Corp (TNXP) has traded red over the past five days. The 5-day price performance for the stock is 33.36%, and 81.90% over 30 days. With these gigs, the year-to-date price performance is -44.85%. Short interest in Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) saw shorts transact 0.55 million shares and set a 0.36 days time to cover.
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
The rating firms project that company’s revenue will grow 9.97% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is 2.6M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 2.8M.Earnings reports from the last fiscal year show that sales brought in 2.48M and 2.21M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 4.75% before jumping 26.81% in the following quarter.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp has its next earnings report out on 2025-Mar-17. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders
In total, 3.32% institutions holds shares in the company.
We also have Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund as the top two Mutual Funds with the largest holdings of the Tonix Pharmaceuticals Holding Corp (TNXP) shares. Going by data provided on Dec 31, 2024 , Fidelity Extended Market Index Fund holds roughly 10.45 shares. This is just over 0.19% of the total shares, with a market valuation of $0.19 million. Data from the same date shows that the other fund manager holds a little less at 4.03, or 0.07% of the shares, all valued at about 73360.0.
